Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Zibelman

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Cancers|August 7, 2021
Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New OpportunitiesKevin Zarrabi, Emily Walzer, Matthew Zibelman
Journal for Immunotherapy of Cancer|February 18, 2016
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumabMatthew Zibelman, Natasha Pollak, Anthony J Olszanski
Urologic Oncology|November 28, 2016
Emerging role of immunotherapy in urothelial carcinoma-Advanced diseaseMatthew Zibelman, Chethan Ramamurthy, Elizabeth R Plimack
European Urology|May 31, 2016
Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?Daniel M Geynisman, Elizabeth R Plimack, Matthew Zibelman
Therapeutic Advances in Medical Oncology|August 8, 2018
Approved checkpoint inhibitors in bladder cancer: which drug should be used when?Pooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.
Current Opinion in Urology|July 20, 2022
The past, present, and future of pT0 in bladder cancer clinical trialsJared P Schober, Elizabeth Plimack, Daniel M Geynisman, et al.
European Urology Focus|May 20, 2019
First-line Immunotherapy in Metastatic Urothelial CarcinomaPooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.
Current Treatment Options in Oncology|February 18, 2017
Checkpoint Inhibitors for the Treatment of Renal Cell CarcinomaPooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional SolutionsSuzanne Cole, Matthew Zibelman, Erin Bertino, et al.
Journal of Palliative Medicine|April 12, 2014
Assessing prognostic documentation and accuracy among palliative care cliniciansMatthew Zibelman, Qun Xiang, Sandra Muchka, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Cancers|August 7, 2021
Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New OpportunitiesKevin Zarrabi, Emily Walzer, Matthew Zibelman
Journal for Immunotherapy of Cancer|February 18, 2016
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumabMatthew Zibelman, Natasha Pollak, Anthony J Olszanski
Urologic Oncology|November 28, 2016
Emerging role of immunotherapy in urothelial carcinoma-Advanced diseaseMatthew Zibelman, Chethan Ramamurthy, Elizabeth R Plimack
European Urology|May 31, 2016
Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?Daniel M Geynisman, Elizabeth R Plimack, Matthew Zibelman
Therapeutic Advances in Medical Oncology|August 8, 2018
Approved checkpoint inhibitors in bladder cancer: which drug should be used when?Pooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.
Current Opinion in Urology|July 20, 2022
The past, present, and future of pT0 in bladder cancer clinical trialsJared P Schober, Elizabeth Plimack, Daniel M Geynisman, et al.
European Urology Focus|May 20, 2019
First-line Immunotherapy in Metastatic Urothelial CarcinomaPooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.
Current Treatment Options in Oncology|February 18, 2017
Checkpoint Inhibitors for the Treatment of Renal Cell CarcinomaPooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional SolutionsSuzanne Cole, Matthew Zibelman, Erin Bertino, et al.
Journal of Palliative Medicine|April 12, 2014
Assessing prognostic documentation and accuracy among palliative care cliniciansMatthew Zibelman, Qun Xiang, Sandra Muchka, et al.
Pageof 6